Biogen, Incorporated

Biogen Idec Ma Inc.

Biogen Ma Inc.

Adrian Whitty

Paula S Hochman

Margot Brickelmaier

Laura Runkel

Blake Pepinsky

Linda C Burkly

Catherine A Hession

Christopher D Benjamin

An interferon beta polypeptide comprising interferon-beta 1a coupled to a polymer containing a polyalkylene glycol moiety wherein the interferon-beta-1a and the polyalkylene glycol moiety are arranged such that the interferon-beta-1a has an enhanced activity relative to another therapeutic form of interferon beta (interferon-beta-1b) and exhibits no decrease in activity as compared to non-conjugated interferon-beta-1a. The conjugates of the invention are usefully employed in therapeutic as well as non-therapeutic, e.g., diagnostic, applications.

Polymer conjugates of interferon beta-1A and uses

A fusion polypeptide is described having the amino acid sequence X-Y-Z, or portion thereof, comprising the amino acid sequence of a glycosylated interferon-beta (X); Y is an optional linker moiety; and Z is a polypeptide comprising at least a portion of a polypeptide other than glycosylated interferon-beta. It is preferred that X is human interferon-beta-1a. Mutants of interferon-beta-1a are also described.

Interferon-beta-1a-immunoglobulin fusion proteins and uses

Polymer conjugates of interferon beta-1a and uses

Interferon-beta fusion proteins and uses

The invention relates to antibodies which specifically bind to the gc chain of cytokine receptors, as well as to cell lines which produce such antibodies, pharmaceutical compositions, and methods of treating immunological diseases by treating patients with such antibodies.

Common gamma chain monoclonal antibody blocking agents

Growing community of inventors

Hopkinton, MA, United States of America

Adrian Whitty